Human Immunodeficiency Virus Patient-Focused Drug Development and Human Immunodeficiency Virus Cure Research: Public Meeting, 29755-29757 [2013-12093]

Download as PDF TKELLEY on DSK3SPTVN1PROD with NOTICES Federal Register / Vol. 78, No. 98 / Tuesday, May 21, 2013 / Notices Purpose: The Board will: (1) Conduct, encourage, cooperate with, and assist other appropriate public health authorities, scientific institutions, and scientists in the conduct of research, investigations, experiments, demonstrations, and studies relating to the causes, diagnosis, treatment, control, and prevention of physical and mental diseases, and other impairments; (2) assist States and their political subdivisions in preventing and suppressing communicable and non-communicable diseases and other preventable conditions and in promoting health and well-being; and (3) conduct and assist in research and control activities related to injury. The Board of Scientific Counselors makes recommendations regarding policies, strategies, objectives, and priorities; and reviews progress toward injury prevention goals and provides evidence in injury prevention-related research and programs. The Board also provides advice on the appropriate balance of intramural and extramural research, the structure, progress and performance of intramural programs. The Board is designed to provide guidance on extramural scientific program matters, including the: (1) Review of extramural research concepts for funding opportunity announcements; (2) conduct of Secondary Peer Review of extramural research grants, cooperative agreements, and contracts applications received in response to the funding opportunity announcements as it relates to the Center’s programmatic balance and mission; (3) submission of secondary review recommendations to the Center Director of applications to be considered for funding support; (4) review of research portfolios, and (5) review of program proposals. Matters to be Discussed: The Board of Scientific Counselors will discuss science matters to include research strategies needed to guide the Center’s focus, as well as updates on the current research portfolio review and the Pediatric mild-Traumatic Injury Workgroup. There will be 15 minutes allotted for public comments at the end of the open session. Closed Session: On the second day of the meeting, the Board will conduct the Secondary Peer Review of extramural research grant applications received in response to Funding Opportunity Announcement CE–13–002 Research Grants for Preventing Violence and Violence Related Injury. Applications will be assessed as it relates to the Center’s mission and programmatic balance. The Board will discuss and vote on the secondary review recommendations to be provided to the Center Director for applications to be considered for funding support. Agenda items are subject to change as priorities dictate. Contact Person for More Information: Gwendolyn H. Cattledge, Ph.D., M.S.E.H., Deputy Associate Director for Science, NCIPC, CDC, 4770 Buford Highway NE., Mailstop F–63, Atlanta, Georgia 30341, Telephone (770) 488–1430. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices VerDate Mar<15>2010 17:07 May 20, 2013 Jkt 229001 pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2013–12037 Filed 5–20–13; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2013–N–0473] Human Immunodeficiency Virus Patient-Focused Drug Development and Human Immunodeficiency Virus Cure Research: Public Meeting AGENCY: Food and Drug Administration, HHS. Notice of public meeting; request for comments. ACTION: SUMMARY: The Food and Drug Administration (FDA) is announcing a public meeting and an opportunity for public comment on human immunodeficiency virus (HIV) PatientFocused Drug Development and HIV Cure Research. Patient-Focused Drug Development is part of FDA’s performance commitments in the fifth authorization of the Prescription Drug User Fee Act (PDUFA V). FDA is interested in obtaining patient input on the impact of HIV on daily life, available therapies to treat the condition, and patients’ views on issues related to HIV cure research, such as perceived benefits and acceptable risks for participating in HIV cure research and clear communication of benefits and risks through informed consent. DATES: The public meeting will be held on Friday, June 14, 2013, from 9:30 a.m. to 5:30 p.m. Registration to attend the meeting must be received by Wednesday, June 5, 2013. Submit electronic or written comments by July 14, 2013. See the SUPPLEMENTARY INFORMATION section for information on how to register for the meeting. ADDRESSES: The meeting will be held at the FDA White Oak Campus, 10903 New Hampshire Ave., Building 31 Conference Center, in section A of the Great Room (Room 1503), Silver Spring, MD 20993. Entrance for the public meeting participants is through Building 1, where routine security check procedures will be performed. For parking and security information, please PO 00000 Frm 00059 Fmt 4703 Sfmt 4703 29755 refer to https://www.fda.gov/AboutFDA/ WorkingatFDA/BuildingsandFacilities/ WhiteOakCampusInformation/ ucm241740.htm. Submit electronic comments to www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm 1061, Rockville, MD 20852. All comments should be identified with the docket number found in brackets in the heading of this document. FDA will post the complete agenda and additional meeting background material approximately 5 days before the meeting at: https://www.fda.gov/ ForIndustry/UserFees/ PrescriptionDrugUserFee/ ucm348598.htm. FOR FURTHER INFORMATION CONTACT: Pujita Vaidya, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 1199, Silver Spring, MD 20993, 301–796– 0684, FAX: 301–847–8443, email: Pujita.Vaidya@fda.hhs.gov. SUPPLEMENTARY INFORMATION: I. Background on Patient-Focused Drug Development FDA has selected HIV to be the focus of a meeting under Patient-Focused Drug Development, an initiative that involves obtaining a better understanding of patients’ perspectives on the severity of the disease and the available therapies for the condition. Patient-Focused Drug Development is being conducted to fulfill FDA performance commitments made as part of the authorization of PDUFA under Title I of the Food and Drug Safety and Innovation Act (FDASIA) (Pub. L. 112– 144). The full set of performance commitments is available on the FDA Web site at https://www.fda.gov/ downloads/forindustry/userfees/ prescriptiondruguserfee/ ucm270412.pdf. FDA has committed to obtain the patient perspective in 20 disease areas during the course of PDUFA V. For each disease area, the Agency will conduct a public meeting to discuss the disease and its impact on patients’ daily lives, the types of treatment benefit that matter most to patients, and patients’ perspectives on the adequacy of the available therapies. These meetings will include participation of FDA review divisions, the relevant patient community, and other interested stakeholders. In the Federal Register of April 11, 2013 (78 FR 21613), FDA published a document that announced the disease E:\FR\FM\21MYN1.SGM 21MYN1 29756 Federal Register / Vol. 78, No. 98 / Tuesday, May 21, 2013 / Notices areas for meetings in fiscal years (FY) 2013 to 2015, the first 3 years of the 5year PDUFA V timeframe. The Agency used several criteria to develop the list of disease areas, outlined in the April 11, 2013, Federal Register document. Public comment on the Agency’s proposed criteria and potential disease areas was gathered through a Federal Register document for public comment that was published on September 24, 2012 (77 FR 58849), and a public meeting that was convened on October 25, 2012. In selecting the set of disease areas, FDA carefully considered the public comments received and the perspectives of review divisions at FDA. By the end of FY 2015, FDA will initiate another public process for determining the disease areas for FY 2016 to 2017. More information, including the list of disease areas and a general schedule of meetings, is posted on FDA’s Web site at https://www.fda.gov/ForIndustry/ UserFees/PrescriptionDrugUserFee/ ucm326192.htm. II. Public Meeting Information TKELLEY on DSK3SPTVN1PROD with NOTICES A. Purpose and Scope of the Meeting As part of Patient-Focused Drug Development, FDA will gather input from HIV patients and patient advocates on current approaches to managing HIV and on symptoms experienced because of HIV or its treatment. FDA is also interested in understanding patients’ perspective on issues related to HIV cure research. For the purposes of this meeting, FDA considers HIV cure research to be any investigation that evaluates a therapeutic intervention intended to control or eliminate HIV infection to the point that no further medical interventions are needed to maintain health. HIV cure research is in early stages of testing in patients, but the products being evaluated may represent important approaches to treating HIV. As in many areas of research, clinical trials studying HIV cure interventions may not provide direct benefit to a participant but may provide scientific information that could guide future research and drug development. Understanding patients’ perspectives on the potential benefits and risks of participating in HIV cure research studies will help FDA evaluate sponsors’ study protocols and informed consent procedures. For each of these topics, a brief initial patient panel discussion will begin the dialogue and will be followed by a facilitated discussion inviting comments from other patient and patient advocates. The draft questions for both meeting topics are as follows: VerDate Mar<15>2010 17:07 May 20, 2013 Jkt 229001 Topic 1: Patients’ perspective on current approaches to managing HIV and on symptoms experienced because of HIV or its treatment 1. What are you currently doing to help manage your HIV and any symptoms you experience because of your condition or other therapies? (Examples may include prescription medicines, over-the-counter products, and non-drug therapies such as diet modification.) 1.1 What specific symptoms do your therapies or treatments address? 1.2 How long have you been on treatment and how has your treatment regimen changed over time? 2. How well does your current treatment regimen treat any significant symptoms of your condition? 2.1 How well have these treatments worked for you as your condition has changed over time? 2.2 Are there symptoms that your current regimen does not address at all, or does not treat as well as you would like? 3. What are the most significant downsides to your current therapies or treatments, and how do they affect your daily life? (Examples of downsides could include bothersome side effects, physical change to your body because of treatment, going to the hospital for treatment, etc.) 4. Of all the symptoms that you experience because of your condition or because of your therapy or treatment, provide one to three symptoms that have the most significant impact on your life? (Examples could include diarrhea, insomnia, difficulty concentrating, etc.) 4.1 Are there specific activities that are important to you but that you cannot do at all or as fully as you would like because of your condition? (Examples of activities may include sleeping through the night, daily hygiene, driving, etc.) 5. Assuming there is currently no complete cure for your condition, what specific things would you look for in an ideal therapy or treatment to manage your condition? Topic 2: Patients’ perspectives on HIV Cure Research 1. What do you believe are the benefits of participating in an HIV cure research study? 2. What would motivate you to participate or to not participate in an HIV cure research study? 3. What risks would you find unacceptable for participating in an HIV cure research study, and why? (Examples of risks that may be associated with participation in an HIV cure research study include common side effects such as nausea and fatigue, PO 00000 Frm 00060 Fmt 4703 Sfmt 4703 and less common but serious adverse events such as blood clots, infection, seizures and cancer.) 4. In certain HIV cure research studies, you would be asked to stop any other HIV medications that you are currently taking. How would this affect your decision whether to participate in an HIV cure research study? 5. The process of informed consent is an important way for the researchers to communicate the purpose of an HIV research study, as well as its expected benefits and potential risks, so that people can make an informed decision whether to participate in the study. 5.1 How should the informed consent clearly communicate to you the purpose of an HIV cure research study, particularly when a study is designed only to provide scientific information that could guide future research and development of treatments? 5.2 How should the informed consent clearly communicate to you the potential benefits of an HIV cure research study? In particular, how should the informed consent describe benefit when we do not think that participants in the study may gain any direct health benefits? 5.3 How should informed consent communicate clearly to you the potential risks of participating in an HIV cure research study? In particular, how should the informed consent describe a study if there is very limited understanding about how the medications or interventions may affect participants or what are the potential risks of those interventions or medications? 5.4 Is there any other information that you would find helpful when deciding whether to enter an HIV cure research study? 6. What else do you want FDA to know about HIV Cure Research from your perspective? B. Attendance and/or Participation in the Meeting If you wish to attend this meeting, visit https:// patientfocusedhiv.eventbrite.com. Please register by June 7, 2013. Those who are unable to attend the meeting in person can register to view a live Web cast of the meeting. You will be asked to indicate in your registration if you plan to attend in person or via the Web cast. Your registration will also contain your complete contact information, including name, title, affiliation, address, email address, and phone number. Seating will be limited, so early registration is recommended. Registration is free and will be on a firstcome, first-served basis. However, FDA E:\FR\FM\21MYN1.SGM 21MYN1 Federal Register / Vol. 78, No. 98 / Tuesday, May 21, 2013 / Notices may limit the number of participants from each organization based on space limitations. Registrants will receive confirmation once they have been accepted. Onsite registration on the day of the meeting will be based on space availability. If you need special accommodations because of disability, please contact Pujita Vaidya (see FOR FURTHER INFORMATION CONTACT) at least 7 days before the meeting. Patients who are interested in presenting comments as part of the initial panel discussions will be asked to indicate in their registration which topic(s) they wish to address. They will also be asked to send via email to PatientFocused@fda.hhs.gov a brief summary of responses to the topic(s) questions. Panelists will be notified of their selection soon after the close of registration on June 5. FDA will try to accommodate all patients and patient advocate participants who wish to speak, either through the panel discussion or audience participation; however the duration of comments may be limited by time constraints. More information will be posted on the meeting Web site at least 5 days before the meeting date. Interested members of the public, including those who attend the meeting in person or through the Web cast, are invited to provide electronic or written responses to any or all of the questions pertaining to Topics 1 and 2 to the Division of Dockets Management (see ADDRESSES). Comments may be submitted until July 14, 2013. Dated: May 15, 2013. Leslie Kux, Assistant Commissioner for Policy. [FR Doc. 2013–12093 Filed 5–20–13; 8:45 am] BILLING CODE 4160–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2013–N–0001] Request for Nominations for Voting Members on Public Advisory Panels or Committees AGENCY: Food and Drug Administration, TKELLEY on DSK3SPTVN1PROD with NOTICES HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is requesting nominations for voting members on the Food Advisory Committee with expertise in microbiology, nutrition, food science, food technology, pediatric development, or nanotechnology in VerDate Mar<15>2010 17:07 May 20, 2013 Jkt 229001 food. Nominations will be accepted for current vacancies and those that will or may occur through June 30, 2013. FDA seeks to include the views of women and men, members of all racial and ethnic groups, and individuals with and without disabilities on its advisory committees, and therefore encourages nominations of appropriately qualified candidates from these groups. DATES: Nominations received on or before July 22, 2013 will be given first consideration for membership on the Food Advisory Committee. Nominations received after July 22, 2013 will be considered for nomination to the committee if nominees are still needed. ADDRESSES: All nominations for membership should be sent electronically to cv@oc.fda.gov, or by mail to Advisory Committee Oversight & Management Staff, 10903 New Hampshire Avenue, Bldg. 32, Rm. 5103, Silver Spring, MD 20993–0002. Information about becoming a member on a FDA advisory committee can also be obtained by visiting FDA’s Web site by using the following link https:// www.fda.gov/AdvisoryCommittees/ default.htm. FOR FURTHER INFORMATION CONTACT: Karen Strambler, Center of Food Safety and Applied Nutrition, Food and Drug Administration, 5100 Paint Branch Ave., Room 1C–016, College Park, MD 20740, 240–402–1913, FAX: 301–436– 2657, email: FoodAdvisoryCommittee@fda.hhs.gov. SUPPLEMENTARY INFORMATION: FDA is requesting nomination for voting members on the Food Advisory Committee. I. General Description of the Committee Duties The Committee provides advice to the Commissioner of Food and Drugs and other appropriate officials, on emerging food safety, food science, nutrition, and other food-related health issues that the FDA considers of primary importance for its food and cosmetics programs. The Committee may be charged with reviewing and evaluating available data and making recommendations on matters such as those relating to: (1) Broad scientific and technical food- or cosmetic-related issues; (2) the safety of new foods and food ingredients; (3) labeling of foods and cosmetics; (4) nutrient needs and nutritional adequacy; and (5) safe exposure limits for food contaminants. The Committee may also be asked to provide advice and make recommendations on ways of communicating to the public the potential risks associated with these PO 00000 Frm 00061 Fmt 4703 Sfmt 4703 29757 issues and on approaches that might be considered for addressing the issues. II. Criteria for Voting Members Members and the Chair are selected by the Commissioner or designee from among individuals knowledgeable in the fields of physical sciences, biological and life sciences, food science, risk assessment, nutrition, food technology, molecular biology, and other relevant scientific and technical disciplines. Members will be invited to serve for terms of up to 4 years. The Committee consists of 17 standing members; of that 15 are voting members, which 2 are technically qualified members identified with consumer interest. In addition to the voting members the Committee has two nonvoting members who are identified with industry interests. III. Nomination Procedures Any interested person may nominate one or more qualified individuals for membership on the advisory committee. Self-nominations are also accepted. Nominations must include a current, complete resume or curriculum vitae for each nominee, including current business address and/or home address, telephone number, and email address if available. Nominations must also specify the advisory committee for which the nominee recommended. Nominations must also acknowledge that the nominee is aware of the nomination unless self-nominated. FDA will ask potential candidates to provide detailed information concerning such matters related to financial holdings, employment, and research grants and/or contracts to permit evaluation of possible sources of conflicts of interest. This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees. Dated: May 15, 2013. Jill Hartzler Warner, Acting Associate Commissioner for Special Medical Programs. [FR Doc. 2013–12071 Filed 5–20–13; 8:45 am] BILLING CODE 4160–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as E:\FR\FM\21MYN1.SGM 21MYN1

Agencies

[Federal Register Volume 78, Number 98 (Tuesday, May 21, 2013)]
[Notices]
[Pages 29755-29757]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-12093]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2013-N-0473]


Human Immunodeficiency Virus Patient-Focused Drug Development and 
Human Immunodeficiency Virus Cure Research: Public Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public meeting; request for comments.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing a public 
meeting and an opportunity for public comment on human immunodeficiency 
virus (HIV) Patient-Focused Drug Development and HIV Cure Research. 
Patient-Focused Drug Development is part of FDA's performance 
commitments in the fifth authorization of the Prescription Drug User 
Fee Act (PDUFA V). FDA is interested in obtaining patient input on the 
impact of HIV on daily life, available therapies to treat the 
condition, and patients' views on issues related to HIV cure research, 
such as perceived benefits and acceptable risks for participating in 
HIV cure research and clear communication of benefits and risks through 
informed consent.

DATES: The public meeting will be held on Friday, June 14, 2013, from 
9:30 a.m. to 5:30 p.m. Registration to attend the meeting must be 
received by Wednesday, June 5, 2013. Submit electronic or written 
comments by July 14, 2013. See the SUPPLEMENTARY INFORMATION section 
for information on how to register for the meeting.

ADDRESSES: The meeting will be held at the FDA White Oak Campus, 10903 
New Hampshire Ave., Building 31 Conference Center, in section A of the 
Great Room (Room 1503), Silver Spring, MD 20993. Entrance for the 
public meeting participants is through Building 1, where routine 
security check procedures will be performed. For parking and security 
information, please refer to https://www.fda.gov/AboutFDA/WorkingatFDA/BuildingsandFacilities/WhiteOakCampusInformation/ucm241740.htm.
    Submit electronic comments to www.regulations.gov. Submit written 
comments to the Division of Dockets Management (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm 1061, Rockville, MD 20852. All 
comments should be identified with the docket number found in brackets 
in the heading of this document.
    FDA will post the complete agenda and additional meeting background 
material approximately 5 days before the meeting at: https://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm348598.htm.

FOR FURTHER INFORMATION CONTACT: Pujita Vaidya, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 51, Rm. 1199, Silver Spring, MD 20993, 301-796-
0684, FAX: 301-847-8443, email: Pujita.Vaidya@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

I. Background on Patient-Focused Drug Development

    FDA has selected HIV to be the focus of a meeting under Patient-
Focused Drug Development, an initiative that involves obtaining a 
better understanding of patients' perspectives on the severity of the 
disease and the available therapies for the condition. Patient-Focused 
Drug Development is being conducted to fulfill FDA performance 
commitments made as part of the authorization of PDUFA under Title I of 
the Food and Drug Safety and Innovation Act (FDASIA) (Pub. L. 112-144). 
The full set of performance commitments is available on the FDA Web 
site at https://www.fda.gov/downloads/forindustry/userfees/prescriptiondruguserfee/ucm270412.pdf.
    FDA has committed to obtain the patient perspective in 20 disease 
areas during the course of PDUFA V. For each disease area, the Agency 
will conduct a public meeting to discuss the disease and its impact on 
patients' daily lives, the types of treatment benefit that matter most 
to patients, and patients' perspectives on the adequacy of the 
available therapies. These meetings will include participation of FDA 
review divisions, the relevant patient community, and other interested 
stakeholders.
    In the Federal Register of April 11, 2013 (78 FR 21613), FDA 
published a document that announced the disease

[[Page 29756]]

areas for meetings in fiscal years (FY) 2013 to 2015, the first 3 years 
of the 5-year PDUFA V timeframe. The Agency used several criteria to 
develop the list of disease areas, outlined in the April 11, 2013, 
Federal Register document. Public comment on the Agency's proposed 
criteria and potential disease areas was gathered through a Federal 
Register document for public comment that was published on September 
24, 2012 (77 FR 58849), and a public meeting that was convened on 
October 25, 2012. In selecting the set of disease areas, FDA carefully 
considered the public comments received and the perspectives of review 
divisions at FDA. By the end of FY 2015, FDA will initiate another 
public process for determining the disease areas for FY 2016 to 2017. 
More information, including the list of disease areas and a general 
schedule of meetings, is posted on FDA's Web site at https://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm326192.htm.

II. Public Meeting Information

A. Purpose and Scope of the Meeting

    As part of Patient-Focused Drug Development, FDA will gather input 
from HIV patients and patient advocates on current approaches to 
managing HIV and on symptoms experienced because of HIV or its 
treatment. FDA is also interested in understanding patients' 
perspective on issues related to HIV cure research. For the purposes of 
this meeting, FDA considers HIV cure research to be any investigation 
that evaluates a therapeutic intervention intended to control or 
eliminate HIV infection to the point that no further medical 
interventions are needed to maintain health. HIV cure research is in 
early stages of testing in patients, but the products being evaluated 
may represent important approaches to treating HIV. As in many areas of 
research, clinical trials studying HIV cure interventions may not 
provide direct benefit to a participant but may provide scientific 
information that could guide future research and drug development. 
Understanding patients' perspectives on the potential benefits and 
risks of participating in HIV cure research studies will help FDA 
evaluate sponsors' study protocols and informed consent procedures.
    For each of these topics, a brief initial patient panel discussion 
will begin the dialogue and will be followed by a facilitated 
discussion inviting comments from other patient and patient advocates. 
The draft questions for both meeting topics are as follows:
    Topic 1: Patients' perspective on current approaches to managing 
HIV and on symptoms experienced because of HIV or its treatment
    1. What are you currently doing to help manage your HIV and any 
symptoms you experience because of your condition or other therapies? 
(Examples may include prescription medicines, over-the-counter 
products, and non-drug therapies such as diet modification.)
    1.1 What specific symptoms do your therapies or treatments address?
    1.2 How long have you been on treatment and how has your treatment 
regimen changed over time?
    2. How well does your current treatment regimen treat any 
significant symptoms of your condition?
    2.1 How well have these treatments worked for you as your condition 
has changed over time?
    2.2 Are there symptoms that your current regimen does not address 
at all, or does not treat as well as you would like?
    3. What are the most significant downsides to your current 
therapies or treatments, and how do they affect your daily life? 
(Examples of downsides could include bothersome side effects, physical 
change to your body because of treatment, going to the hospital for 
treatment, etc.)
    4. Of all the symptoms that you experience because of your 
condition or because of your therapy or treatment, provide one to three 
symptoms that have the most significant impact on your life? (Examples 
could include diarrhea, insomnia, difficulty concentrating, etc.)
    4.1 Are there specific activities that are important to you but 
that you cannot do at all or as fully as you would like because of your 
condition? (Examples of activities may include sleeping through the 
night, daily hygiene, driving, etc.)
    5. Assuming there is currently no complete cure for your condition, 
what specific things would you look for in an ideal therapy or 
treatment to manage your condition?
    Topic 2: Patients' perspectives on HIV Cure Research
    1. What do you believe are the benefits of participating in an HIV 
cure research study?
    2. What would motivate you to participate or to not participate in 
an HIV cure research study?
    3. What risks would you find unacceptable for participating in an 
HIV cure research study, and why? (Examples of risks that may be 
associated with participation in an HIV cure research study include 
common side effects such as nausea and fatigue, and less common but 
serious adverse events such as blood clots, infection, seizures and 
cancer.)
    4. In certain HIV cure research studies, you would be asked to stop 
any other HIV medications that you are currently taking. How would this 
affect your decision whether to participate in an HIV cure research 
study?
    5. The process of informed consent is an important way for the 
researchers to communicate the purpose of an HIV research study, as 
well as its expected benefits and potential risks, so that people can 
make an informed decision whether to participate in the study.
    5.1 How should the informed consent clearly communicate to you the 
purpose of an HIV cure research study, particularly when a study is 
designed only to provide scientific information that could guide future 
research and development of treatments?
    5.2 How should the informed consent clearly communicate to you the 
potential benefits of an HIV cure research study? In particular, how 
should the informed consent describe benefit when we do not think that 
participants in the study may gain any direct health benefits?
    5.3 How should informed consent communicate clearly to you the 
potential risks of participating in an HIV cure research study? In 
particular, how should the informed consent describe a study if there 
is very limited understanding about how the medications or 
interventions may affect participants or what are the potential risks 
of those interventions or medications?
    5.4 Is there any other information that you would find helpful when 
deciding whether to enter an HIV cure research study?
    6. What else do you want FDA to know about HIV Cure Research from 
your perspective?

B. Attendance and/or Participation in the Meeting

    If you wish to attend this meeting, visit https://patientfocusedhiv.eventbrite.com. Please register by June 7, 2013. 
Those who are unable to attend the meeting in person can register to 
view a live Web cast of the meeting. You will be asked to indicate in 
your registration if you plan to attend in person or via the Web cast. 
Your registration will also contain your complete contact information, 
including name, title, affiliation, address, email address, and phone 
number. Seating will be limited, so early registration is recommended. 
Registration is free and will be on a first-come, first-served basis. 
However, FDA

[[Page 29757]]

may limit the number of participants from each organization based on 
space limitations. Registrants will receive confirmation once they have 
been accepted. Onsite registration on the day of the meeting will be 
based on space availability. If you need special accommodations because 
of disability, please contact Pujita Vaidya (see FOR FURTHER 
INFORMATION CONTACT) at least 7 days before the meeting.
    Patients who are interested in presenting comments as part of the 
initial panel discussions will be asked to indicate in their 
registration which topic(s) they wish to address. They will also be 
asked to send via email to PatientFocused@fda.hhs.gov a brief summary 
of responses to the topic(s) questions. Panelists will be notified of 
their selection soon after the close of registration on June 5. FDA 
will try to accommodate all patients and patient advocate participants 
who wish to speak, either through the panel discussion or audience 
participation; however the duration of comments may be limited by time 
constraints.
    More information will be posted on the meeting Web site at least 5 
days before the meeting date. Interested members of the public, 
including those who attend the meeting in person or through the Web 
cast, are invited to provide electronic or written responses to any or 
all of the questions pertaining to Topics 1 and 2 to the Division of 
Dockets Management (see ADDRESSES). Comments may be submitted until 
July 14, 2013.

    Dated: May 15, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013-12093 Filed 5-20-13; 8:45 am]
BILLING CODE 4160-01-P